A Novel Amphiphilic Chitosan-based Injectable Nanogel with Sustain Release of Insulin for Anti-diabetic medication

• Main Authors: Chen,Yi-Chieh, 陳怡潔
• Other Authors: Liu, Dean-Mo
• Format: Others
• Language: en_US
• Published: 2014
• Online Access: http://ndltd.ncl.edu.tw/handle/sgj7m8

碩士 === 國立交通大學 === 材料科學與工程學系所 === 103 === Diabetes is a predominant public health concern, according to International Diabetes Federation (I.D.F), 382 million people are diagnosed with diabetes worldwide in 2013 and this number estimate increase to 592 million in 2035. Since diabetes cannot be cured, diabetic patient require maintaining blood glucose level in normal range through self-management to diminish the risk of complications, such as cardiovascular disease, blindness, kidney failure, and lower limb amputation. Insulin plays an essential role in blood glucose management for both type 1 and some type2 patient. Actually, patients receive insulin treatment via subcutaneous injection more than once a day, which bring suffering and inconvenience. To improve the life quality of diabetic, we successfully developed a novel hydrogel, chitosan based injectable anti-diabetic nanogel. To investigate the degradation behavior, retention weight of nanogel were measure at pre-determined time interval and the degraded products were characterized by FT-IR and 1H magnetic resonance. In vitro drug release studies using insulin revealed that the nanogels exhibited sustained and controllable release. The stability of insulin release from nanogel was investigated by High performance liquid chromatography and circular dichroism. In vitro cell cytotoxicity with HS68 cell shows nanogel exhibit excellent bio-compatibility. The anti-diabetic effect of the nanogel was further explored in diabetic mice, blood glucose levels were measured after s.c injection. The animal experiment result indicated that this anti-diabetic nanogel has a great potential in improving patient compliance, which can reduce the injection frequency.